Capricor Therapeutics (CAPR) Debt to Equity (2016 - 2024)
Historic Debt to Equity for Capricor Therapeutics (CAPR) over the last 15 years, with Q3 2024 value amounting to $0.05.
- Capricor Therapeutics' Debt to Equity rose 10261.87% to $0.05 in Q3 2024 from the same period last year, while for Sep 2024 it was $0.05, marking a year-over-year increase of 10261.87%. This contributed to the annual value of $0.15 for FY2023, which is 4919.53% down from last year.
- Per Capricor Therapeutics' latest filing, its Debt to Equity stood at $0.05 for Q3 2024, which was up 10261.87% from $0.29 recorded in Q2 2024.
- Capricor Therapeutics' 5-year Debt to Equity high stood at $1.24 for Q2 2023, and its period low was -$1.89 during Q3 2023.
- Its 5-year average for Debt to Equity is $0.13, with a median of $0.15 in 2023.
- Within the past 5 years, the most significant YoY rise in Capricor Therapeutics' Debt to Equity was 57083.14% (2023), while the steepest drop was 94195.87% (2023).
- Quarter analysis of 5 years shows Capricor Therapeutics' Debt to Equity stood at $0.12 in 2020, then increased by 5.86% to $0.13 in 2021, then skyrocketed by 131.99% to $0.29 in 2022, then tumbled by 49.2% to $0.15 in 2023, then tumbled by 66.89% to $0.05 in 2024.
- Its Debt to Equity stands at $0.05 for Q3 2024, versus $0.29 for Q2 2024 and $0.18 for Q1 2024.